首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ITaC |
| Uniprot No | O14625 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-94aa |
| 氨基酸序列 | FPMFKRGRCL CIGPGVKAVK VADIEKASIM YPSNNCDKIE VIITLKENKG QRCLNPKSKQ ARLIIKKVER KNF |
| 预测分子量 | 8.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ITAC(干扰素诱导性T细胞α趋化因子，CXCL11)重组蛋白的参考文献示例(注：内容为示例性概括，非真实文献)：
---
1. **标题**: *High-yield production of recombinant human ITAC/CXCL11 in E. coli and functional characterization*
**作者**: Zhang, L. et al.
**摘要**: 研究利用大肠杆菌表达系统高效表达重组人ITAC蛋白，通过优化诱导条件与纯化步骤获得高纯度产物，并通过体外趋化实验验证其诱导T细胞迁移的生物活性。
2. **标题**: *ITAC/CXCL11 recombinant protein enhances antitumor immunity in murine melanoma models*
**作者**: Kim, S. & Park, J.H.
**摘要**: 探讨了重组ITAC蛋白通过招募效应T细胞至肿瘤微环境，增强黑色素瘤小鼠模型的抗肿瘤免疫应答，证明其潜在免疫治疗价值。
3. **标题**: *Comparative analysis of mammalian vs. insect cell systems for ITAC production*
**作者**: Müller, R. et al.
**摘要**: 对比哺乳动物(HEK293)与昆虫(Sf9)细胞系统表达重组ITAC的优缺点，发现哺乳动物系统更利于保留蛋白糖基化修饰及体内稳定性。
4. **标题**: *Structural and functional insights into ITAC/CXCL11 binding to CXCR3 receptor*
**作者**: Gupta, A. et al.
**摘要**: 通过晶体学与分子对接技术解析重组ITAC蛋白与其受体CXCR3的结合机制，为设计靶向趋化因子通路的药物提供结构基础。
---
注：以上文献为示例性内容，实际引用时建议通过PubMed或Google Scholar以“CXCL11 recombinant protein”等关键词检索真实研究。
**Background of ITaC Recombinant Proteins**
Recombinant proteins, engineered through genetic modification, are pivotal tools in biotechnology, medicine, and research. ITaC (Innovative Therapeutic and Catalytic) recombinant proteins represent a specialized class designed for enhanced functionality, stability, and scalability. These proteins are synthesized by inserting target gene sequences into host organisms (e.g., *E. coli*, yeast, or mammalian cells*), enabling precise control over protein expression and post-translational modifications.
ITaC proteins are optimized for therapeutic and diagnostic applications. For instance, they may incorporate fusion tags (e.g., His-tags, Fc regions) to simplify purification or improve pharmacokinetics. Their design often focuses on addressing challenges like immunogenicity, solubility, or short half-life in vivo. In therapeutics, ITaC proteins are leveraged for monoclonal antibodies, enzyme replacements, and cytokine therapies, particularly in oncology, autoimmune diseases, and infectious diseases.
A key innovation lies in ITaC’s modular engineering platforms, which allow rapid customization. Advanced techniques like CRISPR-based gene editing or cell-free protein synthesis systems are employed to accelerate development cycles. Additionally, ITaC emphasizes sustainability, utilizing eco-friendly expression systems to reduce production costs and environmental impact.
In research, these proteins serve as critical reagents for structural studies, drug screening, and mechanistic investigations. Their high purity and batch-to-batch consistency ensure reliability in experimental and clinical settings.
Overall, ITaC recombinant proteins bridge the gap between biotechnological innovation and real-world applications, driving advancements in precision medicine and industrial bioprocessing. Their continued evolution aligns with global demands for safer, more effective biologics and scalable manufacturing solutions.
×
